{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T19:27:14Z","timestamp":1784402834532,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clml.2025.01.018","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T16:31:04Z","timestamp":1738081864000},"page":"512-519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies"],"prefix":"10.1016","volume":"25","author":[{"given":"Michal","family":"Kwiatek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru Subramanian Guru","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2166-3105","authenticated-orcid":false,"given":"Marc","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Tessoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Danilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro J.","family":"Alencar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesquieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishalkumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Guo-Avrutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Pauff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3806-059X","authenticated-orcid":false,"given":"Lindsey E.","family":"Roeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2025.01.018_bib0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.clml.2025.01.018_bib0002","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: from pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clml.2025.01.018_bib0003","first-page":"456","article-title":"Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome","volume":"10","author":"Robertson","year":"1996","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2025.01.018_bib0004","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia","volume":"82","author":"Hanada","year":"1993","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.01.018_bib0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/cdd.2017.189","article-title":"BCL2: a 30-year tale of life, death and much more to come","volume":"25","author":"Pentimalli","year":"2018","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.clml.2025.01.018_bib0006","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ajh.10139","article-title":"Bcl-2 family of proteins in indolent B-cell non-Hodgkin's lymphoma: study of 116 cases","volume":"70","author":"Agarwal","year":"2002","journal-title":"Am J Hematol"},{"issue":"4706","key":"10.1016\/j.clml.2025.01.018_bib0007","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.3874430","article-title":"Involvement of the bcl-2 gene in human follicular lymphoma","volume":"228","author":"Tsujimoto","year":"1985","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.clml.2025.01.018_bib0008","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/cancers12040938","article-title":"BCL-2 proteins in pathogenesis and therapy of B-cell non-hodgkin lymphomas","volume":"12","author":"Klanova","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.01.018_bib0009","unstructured":"US Food and Drug Administration. Venclexta prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208573s024lbl.pdf (Accessed 24 June, 2024)."},{"issue":"12","key":"10.1016\/j.clml.2025.01.018_bib0010","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.01.018_bib0011","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","article-title":"Bcl-2 family proteins are essential for platelet survival","volume":"14","author":"Zhang","year":"2007","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.clml.2025.01.018_bib0012","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1538-7445.AM2021-1258","article-title":"Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor (Abstract no. 1258)","volume":"81","author":"Brandhuber","year":"2021","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.clml.2025.01.018_bib0013","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.2023019706","article-title":"Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy","volume":"143","author":"Liu","year":"2024","journal-title":"Blood"},{"issue":"13_Supplement","key":"10.1016\/j.clml.2025.01.018_bib0014","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1538-7445.AM2021-1258","article-title":"Abstract 1258: preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor","volume":"81","author":"Brandhuber","year":"2021","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.clml.2025.01.018_bib0015","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2025.01.018_bib0016","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMx180018","article-title":"The tumor lysis syndrome","volume":"379","author":"Howard","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clml.2025.01.018_bib0017","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.clml.2025.01.018_bib0018","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.01.018_bib0019","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/10543406.2019.1636811","article-title":"The i3+3 design for phase I clinical trials","volume":"30","author":"Liu","year":"2020","journal-title":"J Biopharm Stat"},{"issue":"23","key":"10.1016\/j.clml.2025.01.018_bib0020","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2025.01.018_bib0021","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/hematology.2020000120","article-title":"Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia","volume":"2020","author":"Fischer","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"8","key":"10.1016\/j.clml.2025.01.018_bib0022","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-Human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clml.2025.01.018_bib0023","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.3390\/cancers13184681","article-title":"Targeting the p53 pathway in CLL: state of the art and future perspectives","volume":"13","author":"Kwok","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T02:22:11Z","timestamp":1749694931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2152265025000345"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}